Back to Results
First PageMeta Content
Pharmaceutical industry / Scientific method / Design of experiments / Pharmacology / Medical ethics / Institutional review board / Clinical trial / Good Clinical Practice / Declaration of Helsinki / Clinical research / Research / Science


DF/HCC Practice Differences in Comparison to ICH GCP Guidelines 1. INTRODUCTORY STATEMENT: Dana-Farber/Harvard Cancer Center (DF/HCC) follows the International Conference on Harmonisation Guidelines for Good Clinical Pra
Add to Reading List

Document Date: 2012-07-03 16:02:31

Open Document

File Size: 60,90 KB

Share Result on Facebook

City

Helsinki / /

Company

Dana / HCC Sponsor-Investigator IND. / /

Country

United States / /

Facility

HCC facility / /

IndustryTerm

insurance statement / product manufacturing record / investigational product / trial site / external site / /

MedicalCondition

DF / disease / severe dementia / only injuries / /

Organization

INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE / Harvard Cancer Center / Association for the Accreditation of Human Research Protection Programs / Institutional Review Board / Food and Drug Administration / IEC / International Rugby Board / Quality Assurance Office / Independent Ethics Committee / IRB / /

Position

investigator / legally acceptable representative / pharmacist / physician / acceptable representative / representative / /

PublishedMedium

the IRB/IEC review / /

Technology

CLINICAL TRIAL PROTOCOL / signed protocol / /

SocialTag